Santaris Pharma discovers and develops RNA-targeted therapies to treat infectious diseases and metabolic disorders. Through its partnerships with pharmaceutical companies, Santaris covers a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders.
Since Gilde invested in Santaris Pharma, the company has advanced its product pipeline through the clinic and signed commercial collaboration agreements with GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche and Shire. Santaris Pharma was acquired by Roche in 2014 for $450M.
Continue reading on Roche.com: Locked Nucleic Acid (LNA) Platform
Since Gilde invested in Santaris Pharma, the company has advanced its product pipeline through the clinic and signed commercial collaboration agreements with GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche and Shire. Santaris Pharma was acquired by Roche in 2014 for $450M.
Continue reading on Roche.com: Locked Nucleic Acid (LNA) Platform
Location: Denmark, Capital Region of Denmark, Hørsholm
Total raised: $14M
Investors 1
| Date | Name | Website |
| - | Gilde Heal... | gildehealt... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.01.2011 | - | $14M | - |
Mentions in press and media 2
| Date | Title | Description |
| 04.01.2011 | Santaris Gets $14M From Pfizer | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Santaris Pharma, the developer of RNA-based therapies in San Diego and Denmark, said today it has expanded its alliance with Pfizer, which has agreed to pay the smaller compan... |
| 19.12.2007 | Life sciences briefing: Wednesday, Dec. 19, 2007 | TODAY’S HEADLINES: Gene-silencing developer Santaris raises €20M (PDF release) Consumer-driven healthcare manager RedBrick Health prescribed $15M (release) Cardiac Dimensions takes in $36M for heart-valve device (release) TcLand Expressions... |